Background: Primary extranodal mucosa-associated lymphoid tissue (MALT) lymphoma in the sellar region is a rare indolent B-cell lymphoma.
Case Presentation: A newly diagnosed patient with MALT lymphoma originating from the pituitary stalk is reported. A space-occupying lesion in the sellar region was found in a 24 year-old man who had no clinical symptoms except for those relating to a sex hormone disorder (rising estrogen and falling androgen) identified during a pre-employment physical examination. MALT lymphoma was diagnosed pathologically. Radiotherapy and chemotherapy were proposed after surgery. However, the patient selected androgen replacement therapy only rather than chemoradiotherapy. Over the next 3 months, no visual disturbance, headache, cranial nerve abnormality, or other symptoms occurred.
Conclusion: Primary sellar region MALT lymphoma is an extremely rare disease. The differential diagnosis of sellar and parasellar masses should include primary sellar region MALT lymphoma. Early detection and treatment of this lymphoma can effectively improve the prognosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406508 | PMC |
http://dx.doi.org/10.3389/fneur.2023.1193391 | DOI Listing |
Rinsho Ketsueki
January 2025
Department of Hematology, Kochi Medical School Hospital, Kochi University.
Primary hepatic lymphoma (PHL) is a lymphoproliferative disorder confined to the liver, with no evidence of lymphomatous involvement in other organs. Here, we report a case of diffuse large B-cell lymphoma (DLBCL)-type PHL in a patient with a long history of primary biliary cholangitis (PBC) and Sjögren's syndrome (SS). A 78-year-old woman presented with epigastralgia and was found to have a solitary liver tumor by contrast-enhanced computed tomography (CT).
View Article and Find Full Text PDFBr J Haematol
January 2025
Department of Nursing, Tohoku Fukushi University, Sendai, Japan.
Zandelisib, a selective, potent PI3Kδ inhibitor, demonstrated favourable outcomes in patients with relapsed or refractory follicular lymphoma in a global phase II study. This phase II study evaluated the efficacy and safety of zandelisib for relapsed or refractory follicular lymphoma or marginal zone lymphoma. Sixty-one patients received zandelisib orally at 60 mg daily continuously in the first two 28-day cycles, followed by intermittent dosing on Days 1-7 following each cycle until progressive disease or unacceptable toxicity.
View Article and Find Full Text PDFArch Med Res
January 2025
Department of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea; Center for Precision Medicine and Genomics, Wonju Severance Christian Hospital, Wonju, South Korea. Electronic address:
Background: Lymphoma is a common hematological malignancy with diverse morphological and immunophenotypic characteristics that may affect treatment and outcomes. Thus, accurate differential diagnosis is crucial, and molecular genetic testing is valuable. We aimed to investigate the genetic characteristics of Korean patients with lymphoma using a next-generation sequencing (NGS)-based targeted panel.
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Department of Urology, Austin Hospital, East Melbourne, Victoria, Australia.
Adenoid cystic carcinoma (AdCC) of the breast is a rare histological subtype of breast cancer, which usually has a low propensity for metastasis and is associated with a good prognosis. AdCC metastasis to the kidney is rare, with only 29 cases reported in the literature. We report a case of a woman in her 60s with multiple right-sided large cystic-solid renal lesions after a recent diagnosis of marginal zone B-cell lymphoma.
View Article and Find Full Text PDFArab J Gastroenterol
January 2025
Division of Gastroenterology and Hepatology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!